Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 12/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.33 |
| ▸ | CDK9 | P50750 | 3/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.32 |
| ▸ | CDK1 | P06493 | 4/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3478727 | 0.89 | ADORA2A (0.52) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL3478716 | 0.85 | ADORA2A (0.37) | ADORA2AADORA3ADORA1ADORA2BCDK1 | |
| SCHEMBL3478693 | 0.84 | ADORA2A (0.46) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL10146715 | 0.83 | ADORA2A (0.46) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL10146195 | 0.83 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13777723 | 0.82 | ADORA2A (0.40) | ADORA2AADORA3ADORA1CDK2ADORA2B | |
| SCHEMBL12374999 | 0.80 | ADORA2A (0.59) | ADORA2AADORA3ADORA1 | |
| SCHEMBL13777745 | 0.78 | ADORA2A (0.45) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL3478715 | 0.78 | ADORA2A (0.47) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13324901 | 0.78 | ADORA2A (0.47) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158604-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152127-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.